Paul Begley

Paul Begley

Auto-generated profile, based on publicly available information

Paul Begley

The University of Manchester

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2011 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
TCThe Human Serum Metabolome (HUSERMET) Consortium
The Human Serum Metabolome (HUSERMET) Consortium
WDWarwick Dunn
Warwick Dunn
DBDavid I Broadhurst
David I Broadhurst
PBPaul Begley
Paul Begley
EZEva Zelena
Eva Zelena
RGRoyston Goodacre
Royston Goodacre

26 January 2009 in Analytical Chemistry
Verified
Journal Article
Closed access
EZEva Zelena
Eva Zelena
WDWarwick Dunn
Warwick Dunn
DBDavid I Broadhurst
David I Broadhurst
SFSue Francis-McIntyre
Sue Francis-McIntyre
KCKathleen M. Carroll
Kathleen M. Carroll
DKDouglas Kell
Douglas Kell

25 July 2014 in Metabolomics
Verified
Journal Article
Open access
PDF file
WDWarwick Dunn
Warwick Dunn
WLWanchang Lin
Wanchang Lin
DBDavid I Broadhurst
David I Broadhurst
PBPaul Begley
Paul Begley
MBMarie Brown
Marie Brown
DKDouglas Kell
Douglas Kell
Phenotyping of 1,200 ‘healthy’ adults from the UK has been performed through the investigation of diverse classes of hydrophilic and lipophilic metabolites present in serum by applying a series of chromatography–mass spectrometry platforms. These data were made robust to instrumental drift by numerical correction; this was prerequisite to allow detection of subtle metabolic differences. The variation in observed metabolite relative concentrations between the 1,200 subjects ranged from less than 5 % to more than 200 %. Variations in metabolites could be related to differences in gender, age, BMI, blood pressure, and smoking. Investigations suggest that a sample size of 600 subjects is both necessary and sufficient for robust analysis of these data. Overall, this is a large scale and non-targeted chromatographic MS-based metabolomics study, using samples from over 1,000 individuals, to provide a comprehensive measurement of their serum metabolomes. This work provides an important baseline or reference dataset for understanding the ‘normal’ relative concentrations and variation in the human serum metabolome. These may be related to our increasing knowledge of the human metabolic network map. Information on the Husermet study is available at http://www.husermet.org/. Importantly, all of the data are made freely available at MetaboLights (http://www.ebi.ac.uk/metabolights/).

9 April 2009 in The Analyst
Verified
Journal Article
Closed access
PDF file
MBM. Brown
M. Brown
WDWarwick Dunn
Warwick Dunn
PDP. Dobson
P. Dobson
YPY. Patel
Y. Patel
CWC. L. Winder
C. L. Winder
DKDouglas Kell
Douglas Kell
The chemical identification of mass spectrometric signals in metabolomic applications is important to provide conversion of analytical data to biological knowledge about metabolic pathways. The complexity of electrospray mass spectrometric data acquired from a range of samples (serum, urine, yeast intracellular extracts, yeast metabolic footprints, placental tissue metabolic footprints) has been investigated and has defined the frequency of different ion types routinely detected. Although some ion types were expected (protonated and deprotonated peaks, isotope peaks, multiply charged peaks) others were not expected (sodium formate adduct ions). In parallel, the Manchester Metabolomics Database (MMD) has been constructed with data from genome scale metabolic reconstructions, HMDB, KEGG, Lipid Maps, BioCyc and DrugBank to provide knowledge on 42,687 endogenous and exogenous metabolite species. The combination of accurate mass data for a large collection of metabolites, theoretical isotope abundance data and knowledge of the different ion types detected provided a greater number of electrospray mass spectrometric signals which were putatively identified and with greater confidence in the samples studied. To provide definitive identification metabolite-specific mass spectral libraries for UPLC-MS and GC-MS have been constructed for 1,065 commercially available authentic standards. The MMD data are available at http://dbkgroup.org/MMD/

16 July 2009 in Analytical Chemistry
Verified
Journal Article
Closed access
PBPaul Begley
Paul Begley
SFSue Francis-McIntyre
Sue Francis-McIntyre
WDWarwick Dunn
Warwick Dunn
DBDavid I Broadhurst
David I Broadhurst
AHAntony Halsall
Antony Halsall
DKDouglas Kell
Douglas Kell

1 June 2016 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Open access
JXJingshu Xu
Jingshu Xu
PBPaul Begley
Paul Begley
SCStephanie J. Church
Stephanie J. Church
SPStefano Patassini
Stefano Patassini
KHKatherine Hollywood
Katherine Hollywood
GCGarth J. S. Cooper
Garth J. S. Cooper
Alzheimer's disease (AD) is an age-related neurodegenerative disorder that displays pathological characteristics including senile plaques and neurofibrillary tangles. Metabolic defects are also present in AD-brain: for example, signs of deficient cerebral glucose uptake may occur decades before onset of cognitive dysfunction and tissue damage. There have been few systematic studies of the metabolite content of AD human brain, possibly due to scarcity of high-quality brain tissue and/or lack of reliable experimental methodologies. Here we sought to: 1) elucidate the molecular basis of metabolic defects in human AD-brain; and 2) identify endogenous metabolites that might guide new approaches for therapeutic intervention, diagnosis or monitoring of AD. Brains were obtained from nine cases with confirmed clinical/neuropathological AD and nine controls matched for age, sex and post-mortem delay. Metabolite levels were measured in post-mortem tissue from seven regions: three that undergo severe neuronal damage (hippocampus, entorhinal cortex and middle-temporal gyrus); three less severely affected (cingulate gyrus, sensory cortex and motor cortex); and one (cerebellum) that is relatively spared. We report a total of 55 metabolites that were altered in at least one AD-brain region, with different regions showing alterations in between 16 and 33 metabolites. Overall, we detected prominent global alterations in metabolites from several pathways involved in glucose clearance/utilization, the urea cycle, and amino-acid metabolism. The finding that potentially toxigenic molecular perturbations are widespread throughout all brain regions including the cerebellum is consistent with a global brain disease process rather than a localized effect of AD on regional brain metabolism.